Sudeep Pharma Downgraded to Reduce, Target Price of Rs 627: Prabhudas Lilladher
Sudeep Pharma
IPOSudeep Pharma Reports Strong Q4FY26 Results, Maintains Growth Momentum
Sudeep Pharma has reported its consolidated revenue for the fourth quarter of fiscal year 2026 (Q4FY26) at Rs1.8 billion, marking a significant growth of 16% year-over-year (YoY) and 6% quarter-over-quarter (QoQ). The company's revenue for the entire fiscal year 2026 (FY26) increased by a substantial 28% YoY to Rs6.4 billion.
The Specialty Ingredients (SI) segment was a key driver of growth, with revenue rising by 105% YoY and 26% QoQ, largely due to higher demand across infant nutrition, medical nutrition, and dietary supplements. The SI business contributed around 44% to FY26 revenue, while EBIT margins remained largely stable.
In contrast, the Pharmaceutical, Food & Nutrition (PFN) segment experienced a decline of 20% YoY and 9% QoQ. However, management expects EBITDA growth of approximately 15% in the PFN business over the fiscal years 2027 and 2028, supported by higher capacity utilization.
Read also: Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data
The company's pCAM project remains on track for Phase-1 commissioning by April 2027, driven by rising global demand and China+1 sourcing opportunities. Management has guided FY27 EBITDA margins of around 37%, while inventory levels are expected to remain high to support customer demand and ensure raw material availability.
Outlook and Valuation
The commissioning of the PFN expansion has been delayed due to customer validation timelines, which are expected to take around 6-12 months. The stock is currently trading at 35x FY28E EPS, while we value the company at 33x FY28E EPS. Based on this analysis, we maintain our 'Reduce' rating with a target price of Rs627.
Financial Performance Comparison
Read also: US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline
| Segment | Q4FY26 Revenue | QoQ Growth | YoY Growth |
|---|---|---|---|
| Specialty Ingredients (SI) | Rs1.2 billion | 26% | 105% |
| Pharmaceutical, Food & Nutrition (PFN) | Rs0.6 billion | -9% | -20% |
Key Highlights
- Consolidated revenue: Rs1.8 billion (Q4FY26)
- FY26 revenue: Rs6.4 billion (28% YoY growth)
- SI segment revenue: Rs1.2 billion (26% QoQ growth, 105% YoY growth)
- PFN segment revenue: Rs0.6 billion (-9% QoQ growth, -20% YoY growth)
Investor Takeaway
Investors should be cautious about Sudeep Pharma's downgrade and target price reduction.
More in Economy
Treasury Yields Experience Largest Increase in Two Weeks Following Release of Labor Market Data
US-Iran Tensions Spark Uptick in Oil Prices Amid Global Market Decline
MoSPI Releases Uniform Norms for DDP Estimates with 2022-23 Base Year
